Literature DB >> 17343588

Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings.

Ghada Bin Saif1, Sultan Al-Khenaizan.   

Abstract

Netherton's syndrome (NS) is a rare autosomal recessive disease comprised of ichthyosis in the form of ichthyosis linearis circumflexa, hair shaft defects and atopic manifestations with an elevated IgE level. Various therapeutic options have been used in NS with variable success. Tacrolimus and pimecrolimus belong to the family of calcineurin inhibitors. They bind cytoplasmic proteins and the resulting complex binds calcineurin, inhibiting its ability to dephosphorylate the nuclear factor of activated T cells, thus suppressing gene transcription. There have been conflicting reports of the usefulness of tacrolimus in NS patients, with systemic absorption being the main adverse outcome. Here we report four Saudi siblings (two boys and two girls) with NS who were treated with topical tacrolimus and pimecrolimus with good control of their skin disease without any toxic effect. To our knowledge, this is the second report of the use of topical pimecrolimus in NS in the English literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343588     DOI: 10.1111/j.1365-4632.2006.02956.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  7 in total

Review 1.  Prenatal diagnosis of Comel-Netherton syndrome with PGD, case report and review article.

Authors:  Banu Bingol; Seval Tasdemir; Ziya Gunenc; Faruk Abike; Semra Esenkaya; Safak Tavukcuoglu; Hakan Berkil
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

2.  [Generalised erythema, scaling and hair anomaly].

Authors:  C Hammer; N Voshege; U Hillen; J Dissemond
Journal:  Hautarzt       Date:  2013-07       Impact factor: 0.751

3.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Timothy G Berger; Alfons Krol; Amy S Paller; Kathryn Schwarzenberger; James N Bergman; Sarah L Chamlin; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; David J Margolis; Robert A Silverman; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2014-05-09       Impact factor: 11.527

4.  Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large-sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin.

Authors:  Zhen Zhang; Chaolan Pan; Ruoqu Wei; Huaguo Li; Yijun Yang; Jiawen Chen; Ming Li; Zhirong Yao
Journal:  Mol Genet Genomic Med       Date:  2021-01-16       Impact factor: 2.183

5.  Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.

Authors:  Wenjie Chen; Veronica A Kinsler; Derek Macmillan; Wei-Li Di
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

Review 6.  Netherton Syndrome in Children: Management and Future Perspectives.

Authors:  Federica Barbati; Mattia Giovannini; Teresa Oranges; Lorenzo Lodi; Simona Barni; Elio Novembre; Ermanno Baldo; Mario Cristofolini; Stefano Stagi; Silvia Ricci; Francesca Mori; Cesare Filippeschi; Chiara Azzari; Giuseppe Indolfi
Journal:  Front Pediatr       Date:  2021-05-10       Impact factor: 3.418

7.  Netherton syndrome, a case report and review of literature.

Authors:  Hassan Boskabadi; Gholamali Maamouri; Shahin Mafinejad
Journal:  Iran J Pediatr       Date:  2013-10       Impact factor: 0.364

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.